ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 8

Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

, , ,

Key opinion leaders investigate the potential impact of redefining small cell lung cancer (SCLC) as a molecularly heterogeneous malignancy on personalized treatment strategies for SCLC subtypes with distinct therapeutic vulnerabilities, while exploring the emerging role of blood-based biomarkers in shaping the evolving treatment landscape for SCLC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
EP. 2: ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
EP. 3: cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
EP. 4: Examining 3-Year Update Data from the CASPIAN Trial
EP. 5: Predictors of Immunotherapy Response in Limited and Extensive SCLC
EP. 6: Overcoming Immunotherapy Resistance in Small Cell Lung Cancer
EP. 7: Examining the use of PD-L1 and tTMB in the CASPIAN Trial
Now Viewing
EP. 8: Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
EP. 9: Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
EP. 10: DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
EP. 11: Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
EP. 12: Examining Key Data from DAREON-8
EP. 13: Closing Thoughts and Key Takeaways on Small Cell Lung Cancer
  1. How redefining SCLC as a molecularly heterogeneous malignancy might better inform personalized treatment of its subtypes with unique therapeutic vulnerabilities.
  2. How the mechanism of promoter methylation levels in ctDNA subtypes contribute to “subtype switching” in relapsed SCLC.
    1. Potential contribution of subtype switching to treatment resistance (platinum-based chemotherapy)
    2. How ‘switching’ to an inflammatory phenotype might improve therapeutic response to immune checkpoint inhibitors vs other SCLC subtypes
    3. The variable response of SCLC subtypes to currently available therapies
  4. Briefly discuss significant adverse events in patients with LS-SCLC who receiveIO-based regimens and explore strategies for their mitigation and management.
x